Literature DB >> 7563391

Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies.

Y Hatta1, T Hirama, S Takeuchi, E Lee, E Pham, C W Miller, T Strohmeyer, S P Wilczynski, S Melmed, H P Koeffler.   

Abstract

PURPOSE: The p16 (MTS1) gene codes for a cyclin-dependent kinase inhibitor and may be a new tumor suppressor gene. It is frequently mutated in a variety of cell lines established from tumors. This is the first report of screening for alteration of the p16 gene in testicular, ovarian and endometrial malignancies.
MATERIALS AND METHODS: We examined alterations of p16 in 78 primary genital tumors (42 testicular, 21 ovarian and 15 endometrial cancers) and mononuclear cells from 2 patients with Lynch syndrome II as well as 5 testicular tumor cell lines by single-strand conformation polymorphism (SSCP) and Southern blot hybridization.
RESULTS: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. Analysis of DNA sequence of these samples revealed a polymorphism at codon 140. Southern blot hybridization detected neither deletions nor rearrangements of the p16 gene in any of the samples.
CONCLUSIONS: Taken together, these results suggest that p16 alterations probably are not important for tumorigenesis of testicular, ovarian and endometrial tumors.

Entities:  

Mesh:

Year:  1995        PMID: 7563391

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

Review 1.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors.

Authors:  P Chaubert; L Guillou; A M Kurt; M M Bertholet; G Metthez; H J Leisinger; F Bosman; P Shaw
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

3.  Aberrant promoter hypermethylation of p16 gene in endometrial carcinoma.

Authors:  Zhuo-ying Hu; Liang-dan Tang; Qin Zhou; Lin Xiao; Yi Cao
Journal:  Tumour Biol       Date:  2015-01-17

Review 4.  Molecular genetics of pineal region neoplasms.

Authors:  M D Taylor; T G Mainprize; J A Squire; J T Rutka
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

5.  p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas.

Authors:  Andrzej Semczuk; Carsten Boltze; Barbara Marzec; Anna Szczygielska; Albert Roessner; Regine Schneider-Stock
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-14       Impact factor: 4.553

6.  Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma.

Authors:  Jyotika Attri; Radhika Srinivasan; Siddhartha Majumdar; Bishan Dass Radotra; Jaidev Wig
Journal:  BMC Gastroenterol       Date:  2005-06-28       Impact factor: 3.067

7.  Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.

Authors:  Y Hatta; S Takeuchi; J Yokota; H P Koeffler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Alteration of p16 and p15 genes in human uterine tumours.

Authors:  R Nakashima; M Fujita; T Enomoto; T Haba; K Yoshino; H Wada; H Kurachi; M Sasaki; K Wakasa; M Inoue; G Buzard; Y Murata
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

9.  CDKN2A gene inactivation in epithelial sporadic ovarian cancer.

Authors:  D Niederacher; H Y Yan; H X An; H G Bender; M W Beckmann
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

Review 10.  Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma.

Authors:  Li Su; Hanwei Wang; Jingwei Miao; Ying Liang
Journal:  Sci Rep       Date:  2015-08-18       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.